Abstract
The effective control of coronavirus disease 2019 (COVID-19) can be achieved by implementing a global vaccination strategy. After millions of mRNA vaccines targeting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been administered worldwide, several reports have shown the cases with gross hematuria following the mRNA vaccine against SARS-CoV2 in patients with glomerulonephritis, especially immunoglobulin A nephropathy (IgAN). In Japan, healthcare workers were initially vaccinated with mRNA vaccines from February 17, 2021, and we experienced the several cases showing gross hematuria after the administration of the second dose of an mRNA vaccine among these vaccinated healthcare workers; thus, we conducted a web-based survey of the councilor members of the Japanese Society of Nephrology to elucidate the frequency and clinical course of gross hematuria after receiving the COVID-19 vaccination.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
